Fortrea Holdings Inc.

NASDAQ:FTRE

Biotechnology

Healthcare
$20.50 -0.46%

-$0.07 today

Market cap
$1.94B
Beta
2.11
P/E (TTM)
-3.1
EPS (TTM)
-$4.90
52W Low $4.36High $18.67

Volume 1.59M

Average 1.31M

FTRE Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Fortrea Holdings Inc.NASDAQ: FTRE

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue dips below year-ago levels

Q2 FY2026 cost of revenue of $539M fell 9.6% year over year, behind the +0.2% change in trailing-twelve-month cost of revenue. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.

Context

  • Cost of revenue amounted to 84.4% of revenue in FY2025, up 4.2 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -9.6% toward the trailing-twelve-month pace of +0.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$539M+1.2% QoQ
Last fiscal yearDec 2025
$2.3B+6.3% YoY
LTMJun 2026
$2.22B+0.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.6%——
1 year+6.3%——
3-year CAGR+2.8%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
2.3B USD
Year-over-year change
+6.3%
4-year CAGR
-1.6%

Cost of Revenue vs competitors

How FTRE compares with its peers on the latest reported figures

  • FTRE's LTM Jun 2026 cost of revenue of $2.22B is the highest of the 3 companies compared; the peer median is $1.09B.
  • Its year-over-year change of +0.2% is the lowest of 3, against a peer median of +18.0%.
  • Cost of revenue amounts to 82.9% of revenue for FTRE, versus a peer median of 56.4%.
FTRE Competitors Peer median
Cost of Revenue for FTRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FTREFortrea Holdings Inc.LTM Jun 2026$2.22B +0.2%+2.8%82.9%
MEDPMedpace Holdings, Inc.LTM Sep 2026$2.01B +23.8%+19.9%70.9%
CERTCertara, Inc.LTM Mar 2026$175.81M +12.1%+6.7%41.9%
Peer median (excluding FTRE) $1.09B+18.0%+13.3%56.4%

Competitors are the stored peer set for FTRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.06B2.84B2.84B2.7B2.72B
Cost of Revenue2.45B2.11B2.25B2.16B2.3B
Gross Profit604.4M724.4M590.6M534.2M425.8M
Gross Margin19.8%25.5%20.8%19.8%15.6%
Research & Development00000
Selling, General & Admin303.1M416.1M448.1M560.7M456.4M
Operating Expenses490.1M537.3M558.6M696.1M456.4M
Depreciation & Amortization166.3M93.6M98M86.9M78M
EBITDA302.9M280.8M137.2M(64.3M)(813.6M)
EBITDA Margin9.9%9.9%4.8%-2.4%-29.9%
Operating Income114.3M187.1M32M(161.9M)(30.6M)
Operating Margin3.7%6.6%1.1%-6.0%-1.1%
Interest Income00000
Interest Expense200K200K69.8M123.8M91.4M
Other Income / Expenses22.1M(100K)(62.5M)(113.1M)(952.4M)
Income Before Tax136.4M187M(30.5M)(275M)(983M)
Pre-Tax Margin4.5%6.6%-1.1%-10.2%-36.1%
Income Tax Expense38.4M41.1M1.2M(3.5M)3.2M
Net Income98M186.2M(25.2M)(328.5M)(986.2M)
Net Margin3.2%6.6%-0.9%-12.2%-36.2%
EPS (Basic)1.112.11(0.04)(3.67)(10.81)
EPS (Diluted)1.112.11(0.04)(3.67)(10.81)
Weighted Avg Shares88.4M88.4M88.8M89.5M91.2M
Weighted Avg Shares (Diluted)88.4M88.4M88.8M89.5M91.2M

Fortrea Holdings Inc.

NASDAQ:FTRE

Intrinsic Alpha fair value

Locked

Current Price

$20.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.